Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1805 results
October 2015
-
Media ReleaseAlcon receives FDA Approval for pre-loaded intraocular lens delivery system to treat patients undergoing cataract surgeryAcrySof® IQ Aspheric Intraocular Lens (IOL) with UltraSertTM Pre-loaded Delivery System helps maintain integrity of incision while facilitating smooth IOL delivery Follows earlier FDA approval…
-
Media ReleaseFDA accepts Sandoz regulatory submission for a proposed biosimilar etanerceptEtanercept is an anti-TNF medicine used to treat a range of immunological diseases including rheumatoid arthritis and psoriasis. Sandoz is seeking approval for all indications included in the…
-
Novartis cancer researchers advance precision medicine
Learn how NIBR uses next generation sequencing to transform clinical trials and diagnostics in oncology.
September 2015
-
Media ReleaseNovartis announces NEJM publication of secukinumab Phase III data confirming significant efficacy in patients with psoriatic arthritisIn the FUTURE 1 study, secukinumab showed rapid and significant efficacy in active psoriatic arthritis (PsA) patients, including improvement of skin and joint disease and reduction in progression of…
-
Heart failure: coping with one of the world’s biggest killers
Patients are learning to live with a chronic disease that will affect one in 5 people over age 40.
-
Media ReleasePatients with aggressive form of melanoma lived for more than two years on average when taking Novartis therapies Tafinlar® + Mekinist®Phase III data showed median overall survival of 25.6 months in patients with BRAF+ V600E/K metastatic melanoma who received Tafinlar + Mekinist Tafinlar + Mekinist combination also demonstrated…
-
Media ReleaseNovartis drug Afinitor® significantly improves progression-free survival in advanced nonfunctional gastrointestinal and lung NETIn pivotal study, everolimus reduced risk of disease progression by 52%; showed 11.0-month median progression-free survival vs 3.9 months for placebo[1] Advanced, progressive, nonfunctional…
-
Media ReleaseNovartis' new heart failure medicine Entresto(TM) recommended by CHMP for EU approvalPositive opinion from EU review body puts Entresto on track to be approved for HFrEF patients across Europe likely by year end Entresto was studied in world's largest heart failure trial which…
-
Media ReleaseNovartis appoints James E. Bradner, MD as President of the Novartis Institutes for BioMedical Research as Mark Fishman retiresNew leader to continue to drive long-term innovation in Novartis research in wide range of therapeutic areas Basel, September 24, 2015 - Novartis announced today that Dr. James (Jay) E.…
-
Media ReleaseNovartis nomme le Dr James E. Bradner Président des Instituts Novartis pour la Recherche Biomédicale suite au prochain départ à la retraite de Mark FishmanUn nouveau responsable pour continuer de stimuler l'innovation à long terme au sein de la recherche chez Novartis dans des domaines thérapeutiques très variés Bâle, le 24 septembre 2015 -…
-
Media ReleaseNovartis ernennt Dr. James E. Bradner zum Präsidenten der Novartis Institutes for BioMedical Research, da Mark Fishman in den Ruhestand trittNeuer Leiter wird weiterhin langfristige Innovationen in zahlreichen Therapiegebieten der Novartis Forschung vorantreiben Basel, 24. September 2015 - Novartis gab heute bekannt, dass…
-
Media ReleaseNovartis launches 'Novartis Access', a portfolio of affordable medicines to treat chronic diseases in lower-income countriesFirst-of-its-kind portfolio approach in healthcare industry, aiming to increase availability and affordability of 15 medicines against cardiovascular diseases, diabetes, respiratory illnesses and…
Pagination
- ‹ Previous page
- 1
- …
- 134
- 135
- 136
- 137
- 138
- 139
- 140
- …
- 151
- › Next page